1 No-Brainer Dividend Stock to Buy on the Dip

Core Viewpoint - AbbVie's recent stock price decline is seen as an overreaction despite solid fourth-quarter results, with a strong long-term outlook remaining intact [1] Group 1: Financial Performance - AbbVie's fourth-quarter revenue increased by 10% year over year to $16.6 billion, driven primarily by immunology medicines Skyrizi and Rinvoq, which showed significant sales growth [2] - Humira, despite being AbbVie's third-best-selling medicine, is experiencing declining sales due to biosimilar competition after losing patent exclusivity in 2023 [4][5] Group 2: Future Growth Prospects - AbbVie projects a sales growth of 9.5% by 2026, with combined sales for Skyrizi and Rinvoq expected to exceed $31 billion, indicating better-than-expected performance [6][7] - The company has a robust pipeline with potential new approvals, including a Parkinson's disease treatment, and has made strategic investments in promising assets [8] Group 3: Dividend and Investment Appeal - AbbVie has a strong dividend track record, having increased its payout for 54 consecutive years, qualifying it as a Dividend King, which enhances its appeal for long-term income investors [9]